Skip to main content
Springer logoLink to Springer
. 2026 Nov 16;91(1):370. doi: 10.1007/s12020-026-04846-7

Hypercalcemia in patients with thyroid cancer: malignancy-related mechanisms, differential diagnosis, and management

Jean Ferrante Mariano 1,2, Marise Lazaretti-Castro 2, Laura Sterian Ward 3, Lucas Leite Cunha 1,4,✉
PMCID: PMC13774331  PMID: 43037843

Abstract

Hypercalcemia associated with malignancy (HAM) represents a critical metabolic oncological emergency that signifies advanced systemic disease and carries prognostic significance. Although its prevalence in thyroid cancer is relatively low, affecting approximately 6.3% of patients in a historical terminal-stage cohort, it serves as a marker for aggressive tumor phenotypes and dedifferentiation. The pathophysiology is categorized into four recognized mechanisms, which may overlap: humoral hypercalcemia of malignancy (HHM) driven by systemic parathyroid hormone-related protein (PTHrP) secretion; local osteolytic hypercalcemia (LOH) resulting from direct bone destruction by metastatic cells; 1,25-dihydroxyvitamin D-mediated hypercalcemia; and the exceedingly rare ectopic secretion of authentic parathyroid hormone (PTH). Notably, anaplastic thyroid cancer (ATC) may present with a dual paraneoplastic syndrome involving concurrent systemic PTHrP secretion and a leukemoid reaction, whereas hypercalcemia in medullary thyroid cancer (MTC) often reflects benign parathyroid pathology associated with multiple endocrine neoplasia type 2 A (MEN2A), which is hypercalcemia in a patient with cancer rather than hypercalcemia caused by the malignancy. Diagnostic evaluation requires a systematic approach organized around PTH-dependent and PTH-independent hypercalcemia, including biochemical assessment of PTH, PTHrP, and vitamin D metabolites, with imaging selected according to tumor histology and the suspected mechanism. Management prioritizes individualized volume repletion, pharmacological suppression of osteoclast activity with denosumab or an intravenous bisphosphonate, current guidance conditionally favouring denosumab, and targeted oncological interventions. Ultimately, the onset of HAM in most thyroid malignancies remains an indicator of poor survival, necessitating a multidisciplinary approach to optimize both clinical outcomes and palliative quality of life. Thyroid-cancer-specific evidence remains limited and is derived largely from case reports and from extrapolation of general hypercalcemia-of-malignancy literature.

Keywords: Hypercalcemia of malignancy (HAM), Thyroid cancer, PTHrP, Anaplastic thyroid carcinoma, Bone metastasis, Paraneoplastic syndrome

Introduction

The intersection of metabolic bone disease and endocrine oncology poses a significant clinical challenge, particularly when it manifests as hypercalcemia associated with malignancy (HAM). As the most frequent metabolic complication of cancer, HAM is estimated to affect between 2% and 30% of patients across the oncological spectrum, with the specific incidence dictated by tumor histology and disease stage [1]. While traditionally associated with malignancies commonly associated with hypercalcemia such as squamous cell lung carcinoma, breast cancer, and multiple myeloma, hypercalcemia in the context of thyroid cancer occupies a unique niche characterized by diverse causes, ranging from hereditary germline syndromes in which the hypercalcemia is not tumor-mediated to rapid somatic dedifferentiation [2–4].

For the purposes of this review, the following definitions are used. Hypercalcemia of malignancy (HAM) refers to hypercalcemia directly caused by the malignant process itself, encompassing humoral hypercalcemia mediated by PTHrP, local osteolytic hypercalcemia, calcitriol-mediated hypercalcemia, and, exceptionally, ectopic PTH secretion. Hypercalcemia in a patient with thyroid cancer is a broader term that includes both HAM and hypercalcemia from causes unrelated to the malignancy, such as MEN2A-associated primary hyperparathyroidism, medication-induced hypercalcemia, immobilization, or granulomatous disease. Paraneoplastic hypercalcemia is used specifically for cases mediated by tumor-derived factors (PTHrP, calcitriol, cytokines). Osteolytic hypercalcemia refers to hypercalcemia driven by local bone destruction at sites of skeletal metastasis. This distinction is maintained throughout the review, and causes unrelated to the malignancy are considered separately below.

The main objective of this narrative review is to provide a comprehensive, up-to-date synthesis of the mechanisms, diagnostic challenges, therapeutic strategies, and prognostic implications of hypercalcemia in patients with thyroid cancer. The literature search is described in the Methods section. Articles were selected based on relevance and quality as defined below, and the information was organized to summarize available evidence while raising new clinically relevant questions.

Methods

A structured literature search was performed in MEDLINE via PubMed on 17 September 2026 using the following query: (“hypercalcemia“[MeSH Terms] OR hypercalcemia[tiab] OR hypercalcaemia[tiab] OR “parathyroid hormone-related protein“[MeSH Terms] OR PTHrP[tiab]) AND (“thyroid neoplasms“[MeSH Terms] OR “thyroid cancer“[tiab] OR “thyroid carcinoma“[tiab]). This retrieved 361 records, reduced to 212 after limiting to English, Portuguese or Spanish and to the period January 1990 to September 2026. Two focused searches were run in parallel: one combining hypercalcemia with the histological subtypes (108 records after the same limits) and one combining PTHrP with thyroid carcinoma (26 records after the same limits). The same search was performed in Embase on the same date using Emtree syntax, retrieving 1,096 records, reduced to 940 after the same limits; of these, 504 were not indexed in MEDLINE. Reference lists of retrieved articles and of relevant reviews were screened manually, and targeted searches were performed for clinical practice guidelines and for the pivotal therapeutic trials cited in the management section. The complete search strategies for all databases, with the interface used, the date of search, the limits applied and the number of records retrieved at each step, are reported in Supplementary Table S1.

Given the rarity of the condition, no study design was excluded a priori: original studies, retrospective cohorts, case series, single case reports, conference abstracts reporting otherwise unpublished thyroid-specific cases, experimental studies and clinical practice guidelines were all eligible. Animal and in vitro studies were used only to support mechanistic discussion and are labelled as such. Article selection was performed by the authors on the basis of three explicit criteria: sample size, availability of biochemical confirmation of the mechanism of hypercalcemia, and specificity to thyroid cancer. Selection was expert appraisal informed by a documented search: titles and abstracts were not screened in duplicate, no formal dual independent selection was undertaken, and we therefore do not report screening or inclusion counts, since such figures would imply a procedure we did not follow. We also included articles encountered outside the formal searches which, in the authors’ judgement, contributed materially to the aims of this review, and these are identified in Table 2. This work is a narrative review and was not registered.

Table 2.

Published studies and reports of hypercalcemia in patients with thyroid malignancy

Study Design Population / number of patients Subtype Mechanism reported Biochemical confirmation available Evidence
Kitamura 1993 [7] Retrospective cohort 127 patients who died from thyroid cancer; 8 with hypercalcemia Mixed, predominantly ATC Humoral inferred in 75% of hypercalcemic cases Limited; PTHrP assay not routinely available at the time [TC]
Nakashima 1995 [29] Tissue study, 107 consecutive thyroid tumours PTC, FTC, ATC and benign lesions All carcinoma subtypes PTHrP expression in 97.6% of carcinomas; ATC strongly positive in all cases Immunohistochemistry, in situ hybridisation and RT-PCR; expression NOT associated with hypercalcemia [TC]
Nakashima 2003 [30] Tissue study 4 ATC containing osteoclast-like giant cells ATC PTHrP and PTH1R expression in osteoclast-like giant cells Immunohistochemistry and in situ hybridisation [TC]
Dackiw 2005 [27] Experimental; 5 presumed ATC cell lines and xenograft ARO, DRO, KAT-4, Hth-74, C-643 (ARO, DRO and KAT-4 subsequently shown to be misidentified [38]) ATC PTHrP expression in all lines; manumycin reduced PTHrP Immunohistochemistry, radioimmunoassay, Western blot [EXP]
Hirose 2026 [8] Case report 1 adult Sporadic MTC Humoral (PTHrP) Calcium 16.5 mg/dL, hypophosphatemia, intact PTH normal, PTHrP elevated; PTHrP normalised after lobectomy [CR]

Ackah 2023

[11]

Conference abstract 1 child (8 years) MTC with MEN2A, metastatic Humoral (PTHrP) Calcium 18.3 mg/dL, PTH 5 pg/mL, PTHrP markedly elevated [CR]
Gerwer 2021 [10] Conference abstract 1 adult ATC arising from a long-standing nodule Humoral (PTHrP) with concurrent leukemoid reaction Calcium 14.7 mg/dL, PTH 4 pg/mL, PTHrP elevated, leukocytes 96,000/microL [CR]
Polymeris 2020 [33] Case report with literature review 1 adult (86 years) ATC Leukemoid reaction attributed to tumour IL-6 Leukocytes 72,470/microL, IL-6 elevated; infection and myeloproliferative disease excluded [CR]
Yazawa 1995 [32] Case report 1 adult (65 years) ATC Concurrent G-CSF and PTHrP production Leukocytosis and hypercalcemia; tumour immunohistochemically positive for both G-CSF and PTHrP [CR]
Iwai 2004 [31] Case report (autopsy) 1 adult (84 years) ATC Humoral hypercalcemia (PTHrP) Calcium 10.9 mg/dL, phosphate 2.2 mg/dL, intact PTHrP 3.2 pmol/L; tumour cells positive for PTHrP(1–34) [CR]

Liao 2026

[37]

Case report 1 adult PTC with liver metastasis Humoral hypercalcemia (PTHrP) from a metastatic deposit Hypercalcemia as presenting feature; PTHrP-secreting liver metastasis identified [CR]
Sharma 2023 [34] Case report 1 adult Primary squamous cell carcinoma of the thyroid Paraneoplastic fever, leukemoid reaction and hypercalcemia Leukocytosis and hypercalcemia with normal TSH; infective workup negative [CR]
Iguchi 1998 [21] Case report 1 adult PTC Ectopic secretion of authentic PTH Elevated PTH with fall after resection of the thyroid tumour [CR]
Kandil 2011 [22] Case report with literature review 1 adult Neuroendocrine tumour (non-thyroid) Ectopic secretion of authentic PTH Immunohistochemical co-expression reported [CR]
Raue 1995 [12] Multicentre cohort (EUROMEN, 1972–1993) 67 patients with MEN2A and PHPT MTC (MEN2A) Primary hyperparathyroidism, not HAM Asymptomatic in 84%, renal stones in 15%, cure in 94%, recurrence in 12% at 8 years [TC]
Larsen 2020 [25] International multicentre registry (19 centres, 17 countries) 1085 MEN2A index cases MTC (MEN2A) Primary hyperparathyroidism, not HAM PHPT was the first manifestation in 0.9%; 9/10 had synchronous MTC [TC]
Pinar-Gutierrez 2023 [57] Multicentre retrospective cohort (Spain) 63 patients with DTC and bone metastases DTC Skeletal-related events SRE in 54%; 5- and 10-year overall survival 42.4% and 20.4% [TC]
Holm 2023 [13] Nationwide population-based cohort (Denmark, 1930–2021) Patients with MEN2A MTC (MEN2A) Primary hyperparathyroidism, not HAM PTH-dependent hypercalcemia [TC]
Farooki 2012 [38] Retrospective cohort 245 patients with DTC and bone metastases DTC Skeletal-related events (composite endpoint including hypercalcemia); 78% had at least one Hypercalcemia not reported separately from the composite endpoint [TC]
Jannin 2022 [58] Bicentric retrospective cohort, congress abstract 178 patients with DTC and bone metastases DTC Skeletal-related events in 71.3%; osteolysis and aggressive histology predictive Hypercalcemia not reported separately; available in abstract form only [CR]

Description: Studies and reports that constitute the thyroid-specific evidence base for this review, with design, population, mechanism and the biochemical confirmation available in each. Conference abstracts and reports available only in abstract form are identified as such. Evidence markers as defined in the Methods

To make the origin and strength of the supporting evidence explicit, statements in the text and tables are annotated as follows: [TC] thyroid-cancer-specific clinical data; [CR] case reports or small case series; [EXP] experimental thyroid cancer models; [EXT] evidence extrapolated from other solid tumors; [GEN] general hypercalcemia-of-malignancy literature or guidelines. These annotations complement, and do not replace, the numbered citations. The marker reflects the nature of the evidence a source contributes, not the format in which it was published: a multicentre cohort reported only as a conference abstract is annotated [TC], with its abstract-only status stated in the Design column of Table 2, whereas a single case described in a full article is annotated [CR].

Epidemiological landscape and the clinical burden of hypercalcemia

Hypercalcemia is recognized as a hallmark of advanced systemic disease in oncology, representing the main cause of elevated serum calcium levels in hospitalized patients [1, 5]. Historically, the prevalence of HAM was thought to be stable, but contemporary data suggest a gradual decline due to earlier use of bone-modifying agents and more effective systemic therapies [1]. In the broader cancer population, HAM is categorized as a metabolic oncological emergency that necessitates urgent intervention to prevent life-threatening cardiovascular and neurological complications [3, 6].

Within thyroid oncology domain, the prevalence of hypercalcemia is relatively low compared to other solid tumors but carries prognostic significance, and estimates vary by more than one order of magnitude according to the population studied [7]. [TC] A landmark study of 127 patients who died from thyroid cancer revealed that approximately 6.3% developed hypercalcemia in the terminal stages of their illness [7, 8]. [TC] This is a highly selected terminal-stage cohort assembled before contemporary systemic therapy, and the figure should not be generalized to all patients with thyroid cancer. We were unable to identify any study reporting the prevalence of hypercalcemia in an unselected thyroid cancer population with a defined denominator; the only population-level data available come from an electronic health record study of all cancer types, which does not report a thyroid-specific rate [9]. [GEN] Of the hypercalcemic cases in that cohort, 75% were attributed to humoral mechanisms, primarily driven by anaplastic thyroid carcinoma (ATC) and, less frequently, papillary or follicular variants [7, 8]. [TC] That proportion likewise reflects a terminal-stage population studied when PTHrP assays were not routinely available, and should not be read as a contemporary mechanistic distribution. This distribution nonetheless underscores a critical clinical reality: while differentiated thyroid cancers (DTC) are common and usually associated with favorable outcomes, the development of hypercalcemia often signals a transition to a more aggressive or dedifferentiated phenotype [1, 7].

Large-scale electronic health record data from the United States indicate that the national prevalence of HAM among all cancer patients remains significant, affecting approximately 2.0% to 2.8% annually [9]. [GEN] For the remaining populations of interest the data are sparse or absent: no reliable estimate exists for hospitalized patients with thyroid cancer, or for patients with metastatic but non-terminal disease. In ATC no denominator-defined estimate exists either: the literature consists of isolated reports, one of which characterises hypercalcemia in ATC as extremely rare [10], [CR] in sporadic MTC tumor-mediated hypercalcemia is exceptional and documented only in isolated case reports [8, 11], [CR] and in MEN2A the reported frequency of primary hyperparathyroidism is 20% to 30%, which is not HAM [12, 13]. [TC]

Table 1 presents the estimated prevalence and primary drivers of hypercalcemia across various cancer types, with the denominator and evidence quality for each. Table 2 lists the individual published studies and reports that constitute the thyroid-specific evidence base for this review.

Table 1.

Estimated prevalence and primary pathophysiological mechanisms of hypercalcemia across selected malignancies and thyroid cancer subtypes

Malignancy / population Estimated prevalence Denominator Disease stage Biochemical or clinical Mechanism biochemically confirmed? Predominant mechanism Reference / evidence Evidence quality
All cancer patients 2.0-2.8% annually Adults with recorded serum calcium and albumin, US oncology practices 2009–2013 All stages Biochemical (corrected serum calcium) Not assessed Variable Gastanaga 2016 [9] [GEN] High (population-based)
Multiple myeloma 7.5–10.2% Same EHR denominator as above All stages Biochemical Not assessed Osteolytic destruction and cytokine release Gastanaga 2016 [9] [GEN] High (population-based)
Prostate cancer 1.4–2.1% Same EHR denominator as above All stages Biochemical Not assessed Osteoblastic metastases; hypercalcemia uncommon Gastanaga 2016 [9] [GEN] High (population-based)
Breast cancer No contemporary denominator-defined estimate identified; figures of 20–30% quoted in the literature refer to advanced cancer in general Not definable from available sources Advanced / metastatic Primarily clinical Yes, in most reported cases Bone metastases and systemic PTHrP [1] [GEN] Low (denominator undefined)
Squamous cell lung cancer No contemporary denominator-defined estimate identified; historically quoted as 10–25% in advanced disease Not definable from available sources Advanced Primarily clinical Yes Humoral (PTHrP) [1] [GEN] Low (denominator undefined)
Thyroid cancer, overall No denominator-defined estimate identified Not definable from available sources All stages - - Variable; frequently not malignancy-mediated [9] [GEN] Absent
Thyroid cancer, terminal stage ~ 6.3% (8/127) Patients who died from thyroid cancer (historical cohort, 1993) Terminal Clinical No; PTHrP assay not routinely available Humoral inferred in 75% of hypercalcemic cases Kitamura 1993 [7] [TC] Low (single historical cohort)
Anaplastic thyroid carcinoma No denominator-defined estimate identified; described as extremely rare in one report Not definable from available sources Late stage Clinical In individual cases only Humoral (PTHrP) [10] [CR] Absent
Medullary thyroid carcinoma, sporadic No denominator-defined estimate identified; tumor-mediated hypercalcemia is documented only in isolated case reports Not definable from available sources All stages Biochemical In individual cases only Humoral (PTHrP), exceptional; or bone metastases [8, 11] [CR] Absent
Medullary thyroid carcinoma, MEN2A 20–30% (PHPT, not HAM) Patients with MEN2A Any Mixed, often asymptomatic Yes (elevated PTH) Primary hyperparathyroidism; PTH-dependent, not malignancy-mediated Raue 1995 [12]; Holm 2023 [13] [TC] Moderate

Description: Comparison of HAM rates and dominant underlying biological pathways. Prevalence figures are interpretable only together with their denominator and disease stage, which are stated for each row. No denominator-defined estimate could be identified for thyroid cancer overall or for anaplastic thyroid carcinoma, and the corresponding rows state this rather than carrying a figure; the 6.3% shown for the terminal-stage cohort refers to a single historical series of patients who died from thyroid cancer. The figures for multiple myeloma and prostate cancer, and the overall estimate of 2.0-2.8%, derive from a population-based electronic health record study in which the denominator was adult patients with recorded serum calcium and albumin; [9] we were unable to identify a contemporary denominator-defined estimate for breast or squamous cell lung cancer, and the figures quoted for these tumors in the literature refer to advanced cancer in general. MEN2A-associated primary hyperparathyroidism is included for completeness but is not hypercalcemia of malignancy

Fundamental pathophysiological mechanisms of HAM

HAM is rarely caused by only one process, but rather a series of complex disruptions of different systems involved in calcium homeostasis, involving bones, kidneys, and the gastrointestinal tract [3, 4, 14]. The development of HAM is generally categorized into four subtypes based on the underlying biological mechanism (Fig. 1). Historically, humoral hypercalcemia has been estimated at approximately 80% of HAM cases and local osteolytic hypercalcemia at approximately 20% [1, 3]. [GEN] These proportions derive from historical general oncology cohorts, do not describe mutually exclusive categories, and have not been validated in thyroid cancer: mixed mechanisms are common, and mechanism assignment depends on how completely the biochemical work-up was performed, which in practice is frequently incomplete. The percentages have accordingly been removed from the panels of Fig. 1.

Fig. 1.

This image explains four distinct but potentially overlapping biological pathways causing hypercalcemia associated with malignancy, detailing their molecular mechanisms and key features:A. Humoral Hypercalcemia of Malignancy (HHM) involves systemic secretion of parathyroid hormone-related protein (PTHrP) by tumor cells. PTHrP binds to the PTH1 receptor, stimulating renal calcium reabsorption in the distal tubule and reducing phosphate reabsorption in the proximal tubule, with typically low or normal levels of active vitamin D (1,25-dihydroxyvitamin D). This leads to increased serum calcium, suppressed native parathyroid hormone (PTH) secretion via negative feedback, and accelerated bone resorption through osteoblast-induced RANKL expression activating osteoclasts.B. Local Osteolytic Hypercalcemia (LOH) occurs when metastatic tumor cells invade bone, releasing cytokines such as interleukin-1, interleukin-6, and tumor necrosis factor-alpha. These cytokines indirectly promote osteoclast maturation and activity through RANKL expression in osteoblast-lineage and stromal cells, causing bone destruction and increased serum calcium. This mechanism is local and not driven by systemic hormones.C. 1,25-dihydroxyvitamin D-mediated hypercalcemia arises from ectopic expression of the enzyme CYP27B1 (1-alpha-hydroxylase) in tumor cells or associated macrophages, converting 25-hydroxyvitamin D to active 1,25-dihydroxyvitamin D (calcitriol). This increases intestinal calcium absorption and bone resorption, raising serum calcium independently of PTH control, with suppressed native PTH levels.D. Ectopic hyperparathyroidism is an exceedingly rare condition where a primary tumor, such as papillary thyroid carcinoma, secretes authentic intact PTH, leading to elevated serum calcium. This diagnosis requires exclusion of primary and other ectopic parathyroid diseases and evidence of tumor PTH production, supported but not confirmed by suppressed native parathyroid glands.Each pathway highlights specific molecular actors, sources of calcium elevation, and feedback effects on native parathyroid hormone secretion, illustrating the complexity and diversity of mechanisms underlying malignancy-associated hypercalcemia.

Pathophysiological subtypes and molecular mechanisms of HAM. Created with BioRender.com. Description: Schematic overview of four pathways, which are not mutually exclusive and may overlap: (A) HHM driven by systemic PTHrP, binding PTH1R, stimulating RANKL and renal calcium retention, with suppressed PTH, elevated PTHrP and hypophosphatemia, and 1,25-(OH)2D typically but not invariably low or normal; PTHrP and PTH share amino-terminal receptor activity but are otherwise distinct peptides; (B) LOH involving direct bone marrow metastasis, tumor-derived cytokines (IL-1, IL-6, TNF-alpha) activating osteoclasts indirectly through RANKL expression in osteoblast-lineage and stromal cells, with mixed humoral and osteolytic mechanisms possible; (C) 1,25-dihydroxyvitamin D-mediated hypercalcemia via ectopic CYP27B1 expression in tumor cells or associated macrophages, with elevated 1,25-(OH)2D and suppressed PTH; (D) Ectopic hyperparathyroidism with authentic PTH secretion by papillary thyroid carcinoma, an exceptional diagnosis requiring exclusion of primary and ectopic parathyroid disease and positive evidence of tumoral PTH production, for which demonstration of suppressed native glands is supportive but not a diagnostic requirement. The historical proportions of approximately 80% humoral and 20% osteolytic derive from general oncology populations and have been removed from the panel titles

Humoral hypercalcemia of malignancy (HHM)

HHM is the most common subtype, accounting for about 80% of all cases in general oncology populations [1, 3]. [GEN] The central mediator is parathyroid hormone-related protein (PTHrP), which shares structural homology with parathyroid hormone (PTH) in its amino-terminal sequence [1, 15]. This homology allows PTHrP to bind to the same PTH-PTHrP type 1 receptor (PTH1R) in the bone and kidneys, although the two peptides are otherwise distinct and their biological actions are not identical [14].

Upon binding to PTH1R, PTHrP induces skeletal activation by stimulating osteoblasts to produce receptor activator of nuclear factor-kappa B ligand (RANKL), which binds RANK on osteoclast precursors, thereby activating osteoclasts and leading to accelerated bone resorption and release of calcium into the bloodstream; osteoprotegerin (OPG), a decoy receptor produced by the same cells, opposes this effect [4, 16]. In the kidneys, PTHrP increases calcium reabsorption in the distal tubules while inhibiting phosphate reabsorption in the proximal tubules, so that hypophosphatemia is a common accompanying finding [1, 15]. The resulting hypercalcemia provides negative feedback to the parathyroid glands, suppressing endogenous PTH secretion.

A distinguishing feature of HHM is that, unlike authentic PTH, PTHrP is less efficient at stimulating 1-alpha-hydroxylase in the kidneys [4, 14]. Consequently, patients with HHM typically exhibit low or inappropriately normal levels of 1,25-dihydroxyvitamin D (calcitriol), providing a useful, although not invariable, biochemical differentiator from primary hyperparathyroidism [4].

Local osteolytic hypercalcemia (LOH)

LOH accounts for approximately 20% of HAM cases in general oncology populations and is characterized by direct bone destruction by metastatic tumor cells [1, 3, 14]. [GEN] While this mechanism is classically driven by high-prevalence malignancies such as breast cancer and multiple myeloma [14] - which are notorious for their profound osteotropism and extensive osteolytic lesions - it is also relevant in differentiated thyroid cancers, where bone is the second most common site for distant metastases after the lung [1, 17]. [TC] In LOH, hypercalcemia is not driven by a systemic hormone but by the local production of bone-resorbing factors within the skeletal microenvironment [16].

Tumor cells infiltrating the bone matrix secrete cytokines such as interleukin-1 (IL-1), IL-6, and tumor necrosis factor-alpha (TNF-alpha), which promote the maturation and activity of osteoclasts predominantly indirectly, by inducing RANKL expression and reducing OPG production in osteoblast-lineage and stromal cells rather than by acting directly on the osteoclast [16, 18]. [EXT] Furthermore, destruction of the bone matrix releases growth factors like transforming growth factor-beta (TGF-beta), which further promote tumor growth, establishing a “vicious cycle” of skeletal destruction and malignancy progression [16, 17]. Two qualifications are important. The presence of osteolytic metastases does not automatically produce systemic hypercalcemia, which develops only when the extent and rate of calcium release exceed renal excretory capacity, often in the presence of dehydration or impaired renal function; [1, 14] [GEN] and although destructive lesions are common in thyroid cancer bone metastases, radiological appearance and biological activity vary, and not all skeletal metastases are uniformly osteolytic [17]. [TC]

1,25-dihydroxyvitamin D-mediated hypercalcemia

This mechanism, while common in hematological malignancies such as Hodgkin lymphoma, is a rare cause of hypercalcemia in solid tumors and has not been convincingly documented as a tumor-mediated mechanism in thyroid carcinoma [19]. [GEN] It results from ectopic expression of the CYP27B1 enzyme (1-alpha-hydroxylase) by malignant cells or associated macrophages, which converts 25-hydroxyvitamin D into the active form, 1,25-dihydroxyvitamin D [19, 20]. The resulting excess of calcitriol leads to increased intestinal calcium absorption and bone resorption, independent of PTH control, and the expected biochemical profile is hypercalcemia with suppressed PTH and elevated 1,25-dihydroxyvitamin D. In a patient with thyroid cancer, an elevated calcitriol concentration should prompt a search for coexisting granulomatous disease or lymphoma before it is attributed to the thyroid tumor [5]. [GEN]

Ectopic hyperparathyroidism

The secretion of authentic, intact PTH by non-parathyroid tumors is an exceedingly rare phenomenon, and it should be regarded as a diagnosis of exclusion rather than an established entity in thyroid oncology. A few cases have been reported in which papillary thyroid carcinoma was suggested to produce PTH, resulting in a clinical profile identical to primary hyperparathyroidism but originating from the thyroid lesion itself [21]. [CR] The clinical recognition of this entity presents a diagnostic challenge, as the hyperfunctioning thyroid mass frequently exhibits radiotracer uptake on 99mTc-sestamibi scintigraphy, convincingly mimicking an intrathyroidal parathyroid adenoma. Before ectopic PTH secretion is invoked, alternative explanations must be excluded, including intrathyroidal parathyroid carcinoma, intrathyroidal parathyroid adenoma, synchronous parathyroid disease, assay interference, and misclassification of tumor origin [22]. [EXT] Supportive features Supportive features include a rapid decline in intraoperative PTH (ioPTH) following resection of the thyroid tumor and immunohistochemical analysis demonstrating the atypical co-expression of classic thyroid markers (e.g., TTF-1) and PTH within the same malignant cell population, ideally corroborated by molecular evidence [22]. [CR] A postoperative fall in PTH is supportive but is not by itself proof of tumor-cell PTH production; demonstration of normal or atrophic native parathyroid glands has been described but is neither universally required nor always achievable, since the glands are frequently neither visualized nor sampled; and immunohistochemistry for PTH is prone to false positivity and must be interpreted with appropriate controls.

HAM in the context of thyroid cancer

Medullary thyroid cancer (MTC)

Medullary thyroid cancer originates from parafollicular C-cells, which physiologically produce calcitonin [23]. This origin creates a unique paradox: although calcitonin typically lowers serum calcium by inhibiting osteoclast activity and increasing renal calcium excretion, its presence in MTC rarely results in clinical hypocalcemia, and serum calcium is typically normal even when calcitonin is markedly elevated [23]. [TC] The mechanisms underlying this tolerance have not been established, and earlier explanations invoking compensatory or paradoxical PTH secretion are not supported by robust data. Hypercalcemia is uncommon in sporadic MTC.

The most frequent cause of hypercalcemia in the MTC population is not the tumor itself but the coexistence of primary hyperparathyroidism (PHPT) in patients with multiple endocrine neoplasia type 2 A (MEN2A), which is hypercalcemia in a patient with cancer rather than hypercalcemia caused by the malignancy [12, 13]. [TC] Approximately 20–30% of MEN2A patients develop parathyroid hyperplasia or adenoma, leading to symptomatic or asymptomatic PHPT [8, 13]. In the EUROMEN series the condition was identified at a median age of 38 years, was asymptomatic in 84% and was associated with nephrolithiasis in about 15%; these figures describe cases registered between 1972 and 1993 rather than a universal presentation [12]. [TC] The diagnostic biochemical signature is hypercalcemia with elevated or inappropriately normal PTH levels [24]. Parathyroidectomy achieved cure in 94% of that cohort, although 13% developed hypoparathyroidism and hypercalcemia recurred in 12% over eight years, so reported cure rates depend on disease extent, operative strategy, duration of follow-up and the definition of cure [12]. [TC] PHPT rarely precedes the tumor: in an international registry of 1085 MEN2A index cases it was the first manifestation in only 0.9% [25]. [TC]

In contrast, MEN2B, another variant characterized by aggressive MTC, pheochromocytoma, and mucosal neuromas, is notably not associated with parathyroid abnormalities, highlighting the genetic specificity of these metabolic manifestations [26].

Beyond its association with MEN2A, MTC rarely causes hypercalcemia through humoral secretion of PTHrP [11]. [CR] Clinical case reports have documented sporadic MTC presenting with severe hypercalcemia (levels as high as 16.5 mg/dL) and elevated serum PTHrP [8]. [CR] Histopathological analysis confirms the presence of PTHrP within the cytoplasm and nuclei of MTC cells, indicating that the tumor has acquired the ability to secrete this paraneoplastic factor [8]. [CR] This phenomenon has also been reported in a pediatric patient with metastatic MTC, described in a conference abstract [11]. [CR] Fewer than ten such cases have been published, and the mechanism should be confirmed biochemically rather than assumed.

Anaplastic thyroid cancer (ATC) and the dual paraneoplastic syndrome

Anaplastic thyroid cancer is the thyroid malignancy with the poorest prognosis [27], known for its rapid growth, extensive local invasion, and high metastatic potential [10]. Among thyroid cancers, ATC is the subtype most consistently associated with HAM, although the supporting evidence consists of case reports, small series and experimental work rather than cohort data [10, 27]. [CR][EXP].

A study involving five presumed ATC cell lines (ARO, DRO, KAT-4, Hth-74, and C-643) reported that all lines robustly express PTHrP [27]. [EXP] This evidence requires qualification: subsequent short tandem repeat profiling showed that ARO and KAT-4 correspond to the HT-29 colon adenocarcinoma line and DRO to the A-375 melanoma line, whereas C-643 and Hth-74 remain authenticated ATC lines, so the observation rests on two authenticated cell lines rather than five [28]. [EXP] Tissue-based human evidence is more informative and more cautionary: in 107 consecutive thyroid tumors, PTHrP was detected in 97.6% of carcinomas and was absent from normal thyroid epithelium, with strong immunoreactivity in every anaplastic case, but expression was not associated with metastasis, calcification or hypercalcemia [29]. [TC] PTHrP and PTH1R have also been demonstrated in osteoclast-like giant cells within ATC tissue [30]. [TC] PTHrP expression is therefore a common feature of thyroid carcinoma tissue rather than a marker of humoral hypercalcemia, and the diagnosis of HHM remains biochemical. Within these limits, PTHrP has been proposed to serve a dual role in ATC: as a systemic mediator of HHM and locally as a protein that inhibits apoptosis and enhances cell proliferation [27]. [EXP] Research showing that modulating PTHrP levels with farnesyltransferase inhibitors (e.g., manumycin) can decrease its synthesis and increase its degradation in cell line models [27] [EXP] has never been tested in humans and should not be presented as a therapeutic option. Two tissue-confirmed case reports support a genuine tumor-mediated mechanism: one autopsy case with PTHrP-dependent hypercalcemia and tumor cells staining for PTHrP(1–34) [31], [CR] and one in which the tumor produced both granulocyte colony-stimulating factor and PTHrP, with immunohistochemical confirmation of both peptides [32]. [CR]

The sudden onset of hypercalcemia paired with significant leukocytosis in a patient with a previously indolent thyroid mass [10] is a clinically important presentation that should raise suspicion for dedifferentiation into ATC [33]. [CR] A leukemoid reaction - defined as persistent white blood cell count exceeding 40,000–50,000/microL, definitions varying - is a diagnosis of exclusion, requiring that infection, hematological malignancy, medication effects and tissue necrosis be ruled out before the leukocytosis is attributed to tumor-derived cytokines such as G-CSF, GM-CSF, IL-1alpha, and IL-6 [33]. [CR] Fewer than ten such cases have been reported in ATC, and the same combination has been described in primary squamous cell carcinoma of the thyroid [34], [CR] so it is suggestive but not pathognomonic. When this inflammatory response occurs concurrently with systemic PTHrP secretion, it signifies a high tumor burden and an acute metabolic emergency [10]. Combined with respiratory failure from local tracheal invasion [33], the appearance of these systemic markers has historically shifted the focus toward palliative care, as median survival was frequently measured in weeks [10]. Treatment decisions, however, require assessment of performance status, airway compromise, resectability, molecular alterations and patient preference: management should follow rapid tissue diagnosis and BRAF V600E testing, and for BRAF V600E-mutated disease combination therapy with dabrafenib and trametinib is approved and has demonstrated a survival benefit, so palliation should not be assumed to be the only option [35, 36]. [TC]

Differentiated thyroid cancer and bone metastasis

While humoral hypercalcemia is less common in differentiated thyroid cancer (DTC), it is not unknown, and a recent report describes hypercalcemia as the presenting feature of a PTHrP-secreting liver metastasis in papillary thyroid carcinoma [37]. [CR] The skeleton remains a frequent site of distant spread for papillary (PTC) and follicular (FTC) variants [17]. [TC] Approximately 80% of skeletal metastases originate from prostate, lung, breast, kidney, and thyroid cancers [16]. [EXT] In the thyroid-specific population, FTC has a higher incidence of bone metastasis (19.2–34.0%) compared to PTC, due to its tendency for hematogenous rather than lymphatic dissemination; these figures derive from selected referral cohorts of patients with metastatic disease and are not incidence figures for unselected patients [17]. [TC] Skeletal morbidity in this population is substantial: in a retrospective series of 245 patients with DTC and bone metastases, 78% presented with or developed at least one skeletal-related event (SRE), with a median time to first SRE of 5 months [38]. [TC] The composite SRE endpoint includes hypercalcemia alongside pathological fracture, spinal cord compression and the need for radiotherapy or surgery to bone, so SRE rates cannot be read as hypercalcemia rates [38]. [TC]

Molecular drivers of bone tropism

The development of skeletal metastases and subsequent local hypercalcemia is a multi-step process (Fig. 2) involving tumor cell adhesion, stromal remodeling, and hijacking of bone homeostasis [17]. In thyroid cancer, primary tumor diameter > 4 cm, vascular invasion, and co-occurrence of BRAF V600E and TERT promoter mutations are associated with aggressive disease and with distant metastasis in general, and may also predispose to bone metastasis; the evidence linking each specifically to bone tropism rather than to distant metastasis at any site is limited and largely indirect, so they are presented here as markers of aggressive disease [17]. [TC] Once within the bone marrow microenvironment, thyroid cancer cells establish a symbiotic relationship with osteoclasts, initiating a process where tumor-derived factors such as PTHrP and IL-6 stimulate osteoblasts and bone marrow stromal cells to overexpress RANKL and reduce OPG [4, 17]. [EXT] This ligand binds to RANK on osteoclast precursors, driving their differentiation and activation [4]. The resulting matrix dissolution releases calcium and sequestered growth factors (TGF-beta, IGFs, FGFs), which reciprocally stimulate tumor cells to produce additional bone-resorbing factors, fueling a “vicious cycle” of skeletal destruction and tumor proliferation [4, 17]. [EXT] The clinical culmination of this localized osteolysis is the efflux of calcium into the systemic circulation. When this release overwhelms renal clearance capacity, it manifests as systemic hypercalcemia, occurring alongside skeletal-related events (SREs) such as pathological fractures, spinal cord compression, and intractable bone pain [17].

Fig. 2.

The image explains the process and consequences of thyroid cancer spreading to bone. It begins with a primary thyroid tumor that can grow larger than four centimeters and invade blood vessels. These features, along with certain genetic mutations like BRAF and TERT, increase the risk of distant metastasis but are not specific to bone spread. The central part illustrates a four-step cycle in bone metastasis: first, tumor cells release cytokines that cause bone-forming cells to increase a molecule called RANKL and decrease its decoy receptor osteoprotegerin; second, RANKL activates precursor cells to become bone-resorbing osteoclasts; third, these osteoclasts break down bone, releasing calcium and growth factors; fourth, the growth factors promote further tumor growth, continuing the cycle. Local calcium release can lead to systemic high blood calcium only if kidney function is overwhelmed. The common clinical outcomes of bone metastasis include pathological fractures, spinal cord compression, severe bone pain, and the need for radiotherapy or orthopedic surgery.

Pathophysiology and clinical consequences of thyroid cancer bone metastasis. Created with BioRender.com. Description: Upper panel: primary tumor expansion (A) and vascular invasion (B) accelerated by high-risk features (C) (diameter > 4 cm, angioinvasion, BRAF V600E and/or TERT promoter mutations), which are associated with distant metastasis in general rather than with bone tropism specifically. Central schema: four-step bone-remodeling loop: (1) tumor-derived PTHrP and IL-6 stimulate RANKL expression, and reduce osteoprotegerin, in osteoblast-lineage and stromal cells; (2) RANKL binds RANK on osteoclast precursors, driving osteoclastogenesis; (3) bone resorption releases Ca2 + and growth factors; (4) growth factors stimulate tumor proliferation, fueling the vicious cycle. Local calcium release produces systemic hypercalcemia only when it exceeds renal excretory capacity, shown as a separate step, and the more common consequences are skeletal-related events (pathological fracture, spinal cord compression, intractable bone pain, need for radiotherapy to bone, need for orthopedic surgery); hypercalcemia is included within the composite SRE endpoint but is not synonymous with it

Hypercalcemia not caused by the malignancy

Because thyroid cancer is common and most patients survive it for many years, much of the hypercalcemia encountered in this population is not HAM, and the following causes should be considered before a paraneoplastic mechanism is invoked. Primary hyperparathyroidism is the most frequent explanation, whether sporadic, coincidental or MEN2A-associated as described above; it is PTH-dependent and is indicated by an elevated or inappropriately normal PTH [5, 12, 13]. [TC] Familial hypocalciuric hypercalcemia should be considered when mild PTH-dependent hypercalcemia is accompanied by low urinary calcium excretion [5]. [GEN] Iatrogenic causes deserve particular emphasis in thyroid oncology: patients with postsurgical hypoparathyroidism receive calcium salts and active vitamin D analogues, and over-replacement is a common and readily reversible cause of hypercalcemia [5]. [GEN] Long-term TSH-suppressive levothyroxine therapy and overt thyrotoxicosis increase bone resorption and may produce mild PTH-independent hypercalcemia, and thiazide diuretics, lithium, vitamin D and vitamin A derivatives, immobilization and adrenal insufficiency should also be considered [5]. [GEN]

Systemic antineoplastic agents used in thyroid cancer are, with rare exceptions, not a cause of hypercalcemia, and the direction of the effect is usually the opposite: multikinase and selective kinase inhibitors, including lenvatinib, sorafenib, vandetanib, cabozantinib, selpercatinib and pralsetinib, reduce osteoclastogenesis and bone turnover and are associated with hypocalcemia, hypophosphatemia and secondary hyperparathyroidism rather than with hypercalcemia [39]. [TC] Where hypercalcemia occurs during systemic therapy, an alternative explanation should be sought before it is attributed to the drug.

Diagnostic evaluation of HAM in thyroid patients

Diagnosis of hypercalcemia in a thyroid cancer patient requires a high index of suspicion and a systematic biochemical and imaging workup, organized around the distinction between PTH-dependent and PTH-independent hypercalcemia, to differentiate between malignancy-related processes and primary parathyroid disorders [1]. A practical sequence is: (1) confirm hypercalcemia and assess severity and symptoms; (2) review medications (thiazides, lithium, calcium, vitamin D, vitamin A), hydration status, renal function, albumin, phosphate, magnesium, creatinine and previous calcium results; (3) measure intact PTH, without delaying urgent therapy; (4) if PTH is suppressed, assess malignancy-related mechanisms (PTHrP, calcitriol) and other PTH-independent causes such as adrenal insufficiency, thyrotoxicosis, immobilization and granulomatous disease; (5) if PTH is elevated or inappropriately normal, evaluate primary hyperparathyroidism, MEN2A-associated disease, familial hypocalciuric hypercalcemia, medications and, exceptionally, ectopic PTH secretion; and (6) select imaging according to histology, prior treatment, symptoms, biochemical profile and the suspected mechanism.

Clinical presentation

Symptoms of HAM correlate with the severity and speed of calcium elevation [15, 40, 41] as shown in Table 3. They depend less on the absolute calcium concentration than on the rate at which it has risen and on age, renal function, hydration status and neurological comorbidity: mild hypercalcemia (< 12 mg/dL) is often asymptomatic or produces only fatigue, constipation and mild cognitive slowing; moderate hypercalcemia (12–14 mg/dL) adds polyuria, polydipsia, nausea, vomiting, abdominal pain, myalgia and confusion; and severe hypercalcemia (> 14 mg/dL) may cause stupor and coma, dehydration, acute kidney injury, shortening of the QT interval and arrhythmia [4, 15, 40, 41]. [GEN] These bands are a guide rather than a treatment threshold, and symptoms may occur at lower concentrations when the rise is rapid.

Table 3.

Clinical grading of hypercalcemia severity based on serum calcium concentrations and associated symptomatology

Severity Serum calcium Common clinical manifestations
Mild < 12 mg/dL Often asymptomatic; fatigue, constipation, mild cognitive slowing
Moderate 12–14 mg/dL Polyuria, polydipsia, nausea, vomiting, abdominal pain, myalgia, confusion
Severe > 14 mg/dL Stupor and coma, dehydration, acute kidney injury, shortened QT interval, arrhythmia

Description: Stratification of hypercalcemic states into mild, moderate, and severe categories, with the stated boundaries inclusive of the quoted values. Symptoms are influenced by the rate of rise, baseline calcium, age, renal function, hydration status and neurological comorbidity, and may occur at lower concentrations when the rise is rapid or be absent at higher concentrations when hypercalcemia is chronic. The clinical manifestations outline progressive neurological, gastrointestinal, renal, and cardiovascular complications

Initial biochemical assessment

The primary objective is to confirm physiologically significant hypercalcemia and evaluate baseline renal function. Total calcium should be interpreted with albumin, recognizing that conventional correction formulae perform poorly in severe illness, marked hypoalbuminemia, renal dysfunction and paraproteinemia [5]. [GEN] While total and albumin-corrected calcium levels exceeding 12 mg/dL suggest increased risk for acute symptoms, measurement of ionized calcium is particularly useful when albumin concentration, acid-base status, paraproteinemia or critical illness complicates interpretation; it is not required in every patient and preanalytical handling is important [1]. [GEN] To differentiate malignancy from primary hyperparathyroidism (PHPT), intact PTH (iPTH) must be assessed; suppressed levels are highly suggestive of HAM [1]. Diagnostic precision is further refined by measuring PTHrP to confirm HHM and evaluating vitamin D metabolites (25-OH and 1,25-(OH)2D) to identify extrarenal calcitriol production; a normal PTHrP does not exclude HAM, since osteolytic and calcitriol-mediated mechanisms remain possible, and assay availability limits its usefulness acutely [8, 15]. [GEN] The calcium-to-creatinine clearance ratio, rather than fractional excretion of calcium, is the measure conventionally used when familial hypocalciuric hypercalcemia (FHH) is suspected; values overlap with PHPT and are influenced by renal function, vitamin D status and thiazide use, and it is not a key test for distinguishing HAM from PHPT when PTH is clearly suppressed [5, 8]. [GEN] Phosphate, magnesium and creatinine or eGFR complete the profile. Finally, in suspected ATC, a complete blood count (CBC) is indispensable to screen for a concurrent leukemoid reaction [10].

Multimodal imaging strategies

Imaging plays a dual role: localizing the primary malignancy and clarifying the etiology of hypercalcemia in diagnostically ambiguous cases, and should follow rather than precede biochemical classification [42]. Neck ultrasonography and CT are fundamental for evaluating the primary thyroid lesion, regional nodal involvement, and potential parathyroid adenomas [42]. Technetium-Sestamibi (99mTc-MIBI) scintigraphy is not a diagnostic test for PHPT but a localization study, indicated once PHPT has been established biochemically and surgery is being considered, and of no value when PTH is suppressed [1, 26]. [GEN] 18 F-fluorocholine PET/CT is a more sensitive alternative for parathyroid localization, with a reported detection rate of 93% compared with 61% for 99mTc-MIBI or tetrofosmin SPECT/CT, and is reasonable when conventional imaging is negative or discordant [43]. [GEN] For suspected skeletal disease, symptom-directed CT or MRI is preferred, and MRI is the modality of choice when spinal cord compression is suspected; bone scintigraphy has reduced sensitivity for purely osteolytic thyroid metastases and has largely been superseded by cross-sectional imaging and FDG-PET/CT in this context [17]. [TC]

Furthermore, FDG-PET/CT provides a comprehensive assessment of systemic metabolic activity, valuable for identifying distant metastases and gauging overall disease burden, both of which correlate significantly with HAM risk and severity; it is useful rather than indispensable and should be requested for a defined clinical question [3, 17]. [TC]

Comprehensive management strategies for HAM

Management of HAM in thyroid cancer is a multi-step process that prioritizes immediate metabolic stabilization, long-term inhibition of bone resorption, and treatment of the underlying malignancy, and should follow current dedicated guidance [44]. [GEN] Box 1 provides a practical algorithmic summary. Hypercalcemia that is not malignancy-mediated is managed according to its own cause.

Box 1. Suggested diagnostic and therapeutic algorithm for hypercalcemia in a patient with thyroid cancer.

  1. Confirm hypercalcemia and assess symptoms, hydration status, renal function and the full medication list, including calcium salts and active vitamin D.

  2. Measure intact PTH, with PTHrP and vitamin D metabolites where indicated, without delaying urgent therapy.

  3. Classify on the basis of PTH and follow the corresponding limb.

  4. PTH elevated or inappropriately normal - PTH-dependent hypercalcemia (PHPT, MEN2A-associated disease, FHH, medications, exceptionally ectopic PTH). Confirm with the calcium-to-creatinine clearance ratio to exclude FHH, review lithium and thiazide exposure, and proceed to localization and parathyroidectomy. Antiresorptive therapy is not the treatment of this group; steps 4 to 9 are used only to control severe hypercalcemia while surgery is arranged.

  5. PTH suppressed - PTH-independent hypercalcemia. Measure PTHrP, 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, and consider non-malignant causes, including over-replacement with calcium salts and active vitamin D after total thyroidectomy, immobilization and granulomatous disease. Where the mechanism is humoral or osteolytic, proceed to steps 4 to 9. Where 1,25-dihydroxyvitamin D is elevated, glucocorticoids are first-line (step 7) and an antiresorptive is added only if severe or symptomatic hypercalcemia persists.

  6. Isotonic saline 0.9% NaCl, rate individualized to hemodynamic status, cardiac and renal function and urine output; avoid a fixed prescription.

  7. Calcitonin 4–8 IU/kg SC/IM q6-12 h for the first 48–72 h in severe or symptomatic cases, as a bridge only.

  8. Antiresorptive therapy: denosumab 120 mg SC (days 1, 8, 15 and 29, then q4w) or zoledronic acid 4 mg IV over at least 15 min, according to renal function and previous exposure.

  9. Glucocorticoids if calcitriol-mediated hypercalcemia is suspected.

  10. Loop diuretic only for fluid overload after volume repletion.

  11. Hemodialysis with low-calcium bath in refractory cases or when fluids are contraindicated.

  12. Monitor calcium, phosphate, magnesium, potassium and creatinine, with ECG where indicated; individualize frequency.

  13. Treat the underlying cancer as per histology and molecular profile, and prevent recurrence with continued antiresorptive therapy; refer for parathyroidectomy if PHPT.

Volume repletion and renal optimization

Severe hypercalcemia is frequently associated with significant volume depletion, driven primarily by gastrointestinal symptoms and hypercalcemia-induced nephrogenic diabetes insipidus [1]. Therefore, the cornerstone of acute management is intravenous repletion with isotonic saline (0.9% NaCl), with the rate individualized according to hemodynamic status, age, cardiac and renal function, urine output and risk of fluid overload; a range of 200–500 mL/h is appropriate for some patients but is unsafe as a blanket prescription [3, 14, 15, 44]. [GEN] Loop diuretics such as furosemide are not a routine method of enhancing calcium clearance and should be reserved for fluid overload after volume repletion, since routine use can worsen dehydration and electrolyte abnormalities [44]. [GEN]

Pharmacological suppression of osteoclast activity

After hemodynamic stabilization, pharmacological intervention targeting bone resorption is initiated to achieve sustained normocalcemia [1]. Current guidance recommends treatment with either denosumab or an intravenous bisphosphonate, with a conditional preference for denosumab, the choice depending on renal function, severity and urgency, previous antiresorptive exposure, risk of hypocalcemia, availability and cost, expected survival, dental status and risk of osteonecrosis of the jaw, and the need for repeat dosing [44]. [GEN]

  • Intravenous bisphosphonates are a first-line option. Zoledronic acid (4 mg IV over no less than 15 min, extended to 30–60 min when eGFR is below 60 mL/min) is the most potent agent, normalizing calcium levels within 2–4 days with effects persisting for weeks [4, 14, 15]. Pamidronate (60–90 mg IV, infused over 2–4 h and extended to 4–6 h in severe renal impairment) is an alternative, with slower onset [1]. Serum creatinine should be measured before each dose. Zoledronic acid is generally avoided when creatinine clearance falls below 30–35 mL/min, where denosumab is preferred because it requires no renal dose adjustment, with the caveat that the risk of hypocalcemia is higher in renal impairment and that calcium and vitamin D status should be corrected and monitored before and during treatment [44]. [GEN]

  • Calcitonin (4–8 IU/kg subcutaneously or intramuscularly every 6–12 h) may be used as a rapid-acting bridge therapy; it inhibits osteoclast activity and increases renal calcium excretion within 4–6 h, but its efficacy is transient, waning after 48–72 h due to receptor downregulation (tachyphylaxis), and it must be combined with a durable antiresorptive agent [44, 45].

  • Denosumab (120 mg subcutaneously on days 1, 8, 15 and 29, then every 4 weeks) is a monoclonal antibody against RANKL, useful in patients with renal failure or those refractory to bisphosphonates [46, 47]. Hypocalcemia is the principal risk, is more frequent in renal impairment and vitamin D deficiency, and mandates monitoring; osteonecrosis of the jaw and atypical femoral fracture are recognized risks of repeated dosing but should not delay treatment of life-threatening hypercalcemia [44, 47]. [GEN]

  • Glucocorticoids (e.g., prednisone 20–40 mg/day for 3–5 days) are first-line for 1,25-(OH)2D-mediated hypercalcemia, as they inhibit extrarenal 1-alpha-hydroxylase activity, with an antiresorptive added if severe or symptomatic hypercalcemia persists [44, 48].

  • Hemodialysis with a low-calcium bath should be considered for selected patients with life-threatening hypercalcemia when severe renal failure, heart failure, inability to tolerate fluids or refractory hypercalcemia prevents adequate conventional treatment [44]. [GEN]

Serum calcium, phosphate, magnesium, potassium and creatinine should be monitored throughout, with electrocardiographic monitoring where clinically indicated, at a frequency individualized according to severity rather than fixed [44]. [GEN]

Targeted oncological intervention

Definitive long-term control of hypercalcemia is contingent upon successful management of the underlying tumor. Surgical resection offers a curative path in rare instances of PTHrP-secreting MTC or ectopic PTH-secreting PTC, resulting in immediate normalization of biochemical markers [8]. For iodine-avid DTC, radioactive iodine (RAI) remains the therapeutic mainstay; in RAI-refractory disease it is ineffective, and options include multikinase inhibitors (lenvatinib, sorafenib) and genotype-directed agents where an actionable alteration is present (RET, NTRK, BRAF), with external-beam radiotherapy, surgical stabilization, ablation or embolization for symptomatic bone metastases and bone-modifying agents for prevention of skeletal-related events [49–51]. [TC] ATC requires rapid tissue diagnosis, BRAF V600E testing, airway assessment and determination of resectability, with combination BRAF/MEK inhibitor therapy for BRAF V600E-positive disease [35, 36]. [TC] The advent of selective RET inhibitors like selpercatinib has substantially improved treatment of RET-mutant MTC, achieving significant cytoreduction; [11, 52] [TC] a parallel effect on tumor-mediated hypercalcemia is plausible but has not been demonstrated systematically. Additionally, calcimimetics such as cinacalcet have been explored in case reports and small series for PTHrP-mediated hypercalcemia, but the evidence is limited, use is off-label in most settings, and cinacalcet does not replace hydration and established antiresorptive therapy; its role is better established in parathyroid carcinoma [53]. [CR]

Prognosis, survival, and the clinical outlook

The development of hypercalcemia in any malignancy is a marker of significant disease progression and poor prognosis [6]. Historically, once HAM presents, survival is measured in weeks to a few months, although this is a historical general observation rather than an inevitable outcome for a contemporary patient [6].

Survival statistics and prognostic indicators

Longitudinal studies consistently demonstrate a poor prognosis: approximately 50% of HAM patients succumb within 30 days and 75% within three months of diagnosis [6, 54]. [GEN] These figures derive from heterogeneous populations and largely antedate genotype-directed treatment. In thyroid oncology, outcomes are strictly modulated by histological subtype, disease extent, treatment era and whether the hypercalcemia is caused by the tumor or by an independent and curable parathyroid disorder. ATC has historically carried a median overall survival of approximately 4 months from diagnosis, with disease-specific mortality approaching 100%; [55] [TC] a nationwide cohort of 812 patients reported a median overall survival of 2.2 months and 1-year survival of 12% [56]. [TC] This course is frequently exacerbated by a concurrent leukemoid reaction [10], but survival has improved in the targeted-therapy era: in a cohort of 479 patients, median overall survival reached 9.5 months, and 1-year survival rose from 35% in 2000–2013 to 59% in 2017–2019, with BRAF/MEK-directed therapy among the factors associated with the improvement [35, 36, 55]. [TC] For DTC, no reliable survival estimate specific to the onset of hypercalcemia exists; outcomes depend chiefly on radioiodine avidity and response to kinase inhibitors and are highly variable [17]. [TC] Conversely, hypercalcemia in MEN2A-associated MTC confers an excellent prognosis, as it usually reflects benign parathyroid pathology rather than cancer progression [12], while the outlook for PTHrP-secreting MTC remains highly variable and potentially curable by surgery [8]. Multivariable analyses further identify ECOG performance status, altered mental status at presentation, and hypoalbuminemia as critical prognostic determinants [54]. Ultimately, the presence of hypercalcemia serves as a vital clinical marker of a biologically aggressive tumor phenotype, often carrying greater prognostic weight than the absolute serum calcium concentration itself [53].

Quality of life and palliative considerations

For patients with refractory hypercalcemia and terminal thyroid cancer, care goals often shift toward symptom palliation [53]. Hypercalcemia-related symptoms such as nausea, confusion, and profound fatigue significantly impact quality of life [5]. While anti-resorptive therapies can normalize calcium levels, they do not always lead to concomitant improvement in survival unless the tumor itself is responsive to therapy [53]. Clinicians must engage in transparent discussions with patients and families regarding the limitations of intensive metabolic correction in the setting of advanced, treatment-refractory malignancy [53]. Palliative care should be presented as compatible with active cancer treatment rather than only as an end-stage alternative [35].

Limitations

This narrative review has several inherent limitations. First, the available literature on HAM in thyroid cancer consists predominantly of case reports, small case series, and retrospective cohort studies, with no randomized controlled trials, and individual patients may have been reported more than once across publications. Second, the low prevalence of the condition (especially in DTC and MTC) limits statistical power and generalizability of findings. Third, heterogeneity in diagnostic criteria, calcium measurement methods, and definitions of hypercalcemia across studies complicates direct comparison of epidemiological data. Fourth, publication bias is likely, as negative or non-significant associations may be underreported. Fifth, a substantial part of the pathophysiology discussed is extrapolated from non-thyroid malignancies, and part of the historical experimental evidence derives from cell lines subsequently shown to be misidentified. Sixth, prognostic data are strongly affected by treatment era and antedate BRAF/MEK- and RET-directed therapy. Finally, although the searches are documented and reproducible, article selection was expert appraisal rather than systematic screening: records were not screened in duplicate, and some articles were included because the authors judged them to contribute to the review, so selection bias cannot be excluded. Future prospective registries and collaborative multicenter studies are needed to better define the natural history and optimal management of HAM in thyroid cancer patients.

Conclusion

Hypercalcemia in patients with thyroid cancer is a rare but clinically significant phenomenon that spans the entire histological spectrum of the disease - from the hereditary associations of MEN2A-related hyperparathyroidism in MTC, which is not caused by the tumor and is usually curable, to the humoral and leukemoid syndromes of ATC. Distinguishing hypercalcemia caused by the malignancy from hypercalcemia in a patient who has a malignancy is the first and most consequential step, and it rests on a single measurement of intact PTH. While the primary mechanisms (systemic PTHrP secretion and local osteolytic bone destruction) are well characterized in general oncology, thyroid-specific evidence remains limited, and PTHrP expression in thyroid carcinoma tissue is common and does not by itself indicate a humoral mechanism. The integration of rapid-acting agents (calcitonin), potent long-term inhibitors (zoledronic acid, denosumab), and targeted therapies (e.g., selpercatinib, dabrafenib/trametinib) offers the best hope for metabolic control. However, the prognosis for most thyroid cancer patients who develop HAM remains poor, underscoring the need for early detection of aggressive tumor phenotypes and continued research into the molecular drivers of PTHrP-mediated and osteolytic disease. Ultimately, successful treatment of hypercalcemia in thyroid oncology is inextricably linked to that of the underlying malignancy, making a multidisciplinary approach essential for optimizing both clinical outcomes and patient quality of life.

Supplementary information

Below is the link to the electronic supplementary material.

Supplementary Material 1 (37.7KB, docx)

Acknowledgments

The following authors received individual support from FAPESP: Jean Ferrante Mariano (2025/28717-3) and Lucas Leite Cunha (2025/08962-3).

Author contributions

J.F.M. performed the literature search, data extraction, and wrote the initial draft. M.L.C. contributed to pathophysiology and diagnostic sections. L.S.W. contributed to the editing of the text and the overall writing of the manuscript. L.L.C. conceived the review, supervised the work, revised all sections critically, and approved the final version. All authors approved the submitted version.

Funding

The Article Processing Charge (APC) for the publication of this research was funded by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil (CAPES) (ROR identifier: 00x0ma614).

Data availability

No datasets were generated or analysed during the current study.

Declarations

Competing interests

The authors declare no competing interests.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1007/s12020-026-04846-7.

Footnotes

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.C. Anastasopoulou, P. Mewawalla, Malignancy-Related Hypercalcemia (In: StatPearls. StatPearls Publishing, Treasure Island (FL), 2026) [PubMed] [Google Scholar]
  • 2.Y. Ni, S. Seballos, S. Ganapathi et al., Germline and somatic SDHx alterations in apparently sporadic differentiated thyroid cancer. Endocr. Relat. Cancer. 22, 121–130 (2015). 10.1530/ERC-14-0537 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.B. Yunita, R. Cahyanur, Pathophysiology and management of hypercalcemia in malignancy. Asian J. Oncol. 9, 12 (2023). 10.25259/ASJO-2022-27-(371) [DOI] [Google Scholar]
  • 4.P. Bartkiewicz, D. Kunachowicz, M. Filipski et al., Hypercalcemia in Cancer: Causes, Effects, and Treatment Strategies. Cells. 13, 1051 (2024). 10.3390/cells13121051 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.M.D. Walker, E. Shane, Hypercalcemia: A Review. JAMA 328, 1624 (2022). 10.1001/jama.2022.18331 [DOI] [PubMed] [Google Scholar]
  • 6.S. Gupta, A. Rastogi, P. Singh et al., (2023) Treatment Outcomes and Survival in Hypercalcemia of Malignancy: A Grave Metabolic Emergency. Cureus. 10.7759/cureus.35783 [DOI] [PMC free article] [PubMed]
  • 7.Y. Kitamura, N. Ishikawa, M. Kohno et al., CLINICAL STUDY OF THYROID CANCER WITH HYPERCALCEMIA. J. Jpn Pract. Surg. Soc. 54, 1701–1705 (1993). 10.3919/ringe1963.54.1701 [DOI] [Google Scholar]
  • 8.T. Hirose, H. Nakayama, O. Matsubara et al., Humoral Hypercalcemia of Malignancy Caused by Parathyroid Hormone-Related Protein-Secreting Medullary Thyroid Carcinoma: A Case Report. Surg. Case Rep. 12 (2026). 10.70352/scrj.cr.25-0546. :n/a [DOI] [PMC free article] [PubMed]
  • 9.V.M. Gastanaga, L.S. Schwartzberg, R.K. Jain et al., Prevalence of hypercalcemia among cancer patients in the United States. Cancer Med. 5, 2091–2100 (2016). 10.1002/cam4.749 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.J.E. Gerwer, R.L. Thomas, R.K. Orosco et al., Leukocytosis and PTHrP-Mediated Hypercalcemia: Ominous Signs in an Indolent Thyroid Nodule. J. Endocr. Soc. 5, A892–A893 (2021). 10.1210/jendso/bvab048.1822 [DOI] [Google Scholar]
  • 11.S.A. Ackah, L.A. DiMeglio, J.C. Sanchez, G.C. Geddes, SAT581 Parathyroid Hormone Related Protein-induced Hypercalcemia In Medullary Thyroid Carcinoma In Pediatric Patient With MEN2A. J. Endocr. Soc. 7 (2023). 10.1210/jendso/bvad114.1518. :bvad114.1518 [DOI]
  • 12.F. Raue, J.L. Kraimps, H. Dralle et al., Primary hyperparathyroidism in multiple endocrine neoplasia type 2A. J. Intern. Med. 238, 369–373 (1995). 10.1111/j.1365-2796.1995.tb01212.x [DOI] [PubMed] [Google Scholar]
  • 13.M. Holm, P. Vestergaard, M. Poulsen et al., Primary Hyperparathyroidism in Multiple Endocrine Neoplasia Type 2A in Denmark 1930–2021: A Nationwide Population-Based Retrospective Study. Cancers. 15, 2125 (2023). 10.3390/cancers15072125 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.A. Mirrakhimov, Hypercalcemia of malignancy: An update on pathogenesis and management. North. Am. J. Med. Sci. 7, 483 (2015). 10.4103/1947-2714.170600 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.E. Almuradova, I. Cicin, Cancer-related hypercalcemia and potential treatments. Front. Endocrinol. 14, 1039490 (2023). 10.3389/fendo.2023.1039490 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.U.H. Weidle, F. Birzele, G. Kollmorgen, R. Rüger, Molecular Mechanisms of Bone Metastasis. Cancer Genomics Proteom. 13, 1–12 (2016) [PubMed] [Google Scholar]
  • 17.S. Huang, Y. Shen, H. Li et al., Bone metastases from endocrine cancer: advances in diagnosis, treatment, and prevention. Front. Endocrinol. 16, 1669154 (2025). 10.3389/fendo.2025.1669154 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.P. Palmqvist, P. Lundberg, I. Lundgren et al., IL-1beta and TNF-alpha regulate IL-6-type cytokines in gingival fibroblasts. J. Dent. Res. 87, 558–563 (2008). 10.1177/154405910808700614 [DOI] [PubMed] [Google Scholar]
  • 19.R. Rodríguez-Gutiérrez, M.A. Zapata-Rivera, D.L. Quintanilla-Flores et al., 1,25-dihydroxyvitamin D and PTHrP mediated malignant hypercalcemia in a seminoma. BMC Endocr. Disord. 14, 32 (2014). 10.1186/1472-6823-14-32 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.S.B. Shivnani, J.M. Shelton, J.A. Richardson, N.M. Maalouf, Hypercalcemia of Malignancy with Simultaneous Elevation in Serum Parathyroid Hormone-Related Peptide and 1,25-Dihydroxyvitamin D in a Patient with Metastatic Renal Cell Carcinoma. Endocr. Pract. 15, 234–239 (2009). 10.4158/EP.15.3.234 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.H. Iguchi, C. Miyagi, K. Tomita et al., Hypercalcemia Caused by Ectopic Production of Parathyroid Hormone in a Patient with Papillary Adenocarcinoma of the Thyroid Gland. J. Clin. Endocrinol. Metab. 83, 2653–2657 (1998). 10.1210/jcem.83.8.5025 [DOI] [PubMed] [Google Scholar]
  • 22.E. Kandil, S. Noureldine, M.A. Khalek et al., Ectopic secretion of parathyroid hormone in a neuroendocrine tumor: a case report and review of the literature. Int. J. Clin. Exp. Med. 4, 234–240 (2011) [PMC free article] [PubMed] [Google Scholar]
  • 23.A. Kiriakopoulos, P. Giannakis, E. Menenakos, Calcitonin: current concepts and differential diagnosis. Ther. Adv. Endocrinol. Metab. 13, 20420188221099344 (2022). 10.1177/20420188221099344 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.L. Kvols, (2003) Parathyroid carcinomas, pheochromocytomas, and multiple endocrine neoplasia syndromes. In: Holland-Frei Cancer Medicine, 6th ed. BC Decker, Hamilton (ON)
  • 25.L.V. Larsen, D. Mirebeau-Prunier, T. Imai et al., Primary hyperparathyroidism as first manifestation in multiple endocrine neoplasia type 2A: an international multicenter study. Endocr. Connect. 9, 489–497 (2020). 10.1530/EC-20-0163 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.C. Eng, G. Plitt, Multiple Endocrine Neoplasia Type 2 [PubMed]
  • 27.A. Dackiw, J. Pan, G. Xu, S.-C.J. Yeung, Modulation of parathyroid hormone-related protein levels (PTHrP) in anaplastic thyroid cancer. Surgery. 138, 456–463 (2005). 10.1016/j.surg.2005.06.033 [DOI] [PubMed] [Google Scholar]
  • 28.R.E. Schweppe, J.P. Klopper, C. Korch et al., Deoxyribonucleic Acid Profiling Analysis of 40 Human Thyroid Cancer Cell Lines Reveals Cross-Contamination Resulting in Cell Line Redundancy and Misidentification. J. Clin. Endocrinol. Metab. 93, 4331–4341 (2008). 10.1210/jc.2008-1102 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.M. Nakashima, A. Ohtsuru, W.T. Luo et al., Expression of parathyroid hormone-related peptide in human thyroid tumours. J. Pathol. 175, 227–236 (1995). 10.1002/path.1711750211 [DOI] [PubMed] [Google Scholar]
  • 30.M. Nakashima, T. Nakayama, A. Ohtsuru et al., Expression of Parathyroid Hormone (PTH)-related Peptide (PTHrP) and PTH/PTHrP Receptor in Osteoclast-like Giant Cells. Pathol. - Res. Pract. 199, 85–92 (2003). 10.1078/0344-0338-00359 [DOI] [PubMed] [Google Scholar]
  • 31.H. Iwai, Y. Ohno, N. Aoki, Anaplastic Thyroid Carcinoma with Humoral Hypercalcemia of Malignancy (HHM): An Autopsy Case Report. Endocr. J. 51, 303–310 (2004). 10.1507/endocrj.51.303 [DOI] [PubMed] [Google Scholar]
  • 32.S. Yazawa, H. Toshimori, K. Nakatsuru et al., Thyroid Anaplastic Carcinoma Producing Granulocyte-Colony-Stimulating Factor and Parathyroid Hormone-Related Protein. Intern. Med. 34, 584–588 (1995). 10.2169/internalmedicine.34.584 [DOI] [PubMed] [Google Scholar]
  • 33.A. Polymeris, C. Kogia, D. Ioannidis et al., Excessive Leukocytosis Leading to a Diagnosis of Aggressive Thyroid Anaplastic Carcinoma: A Case Report and Relevant Review. Eur. Thyroid J. 9, 162–168 (2020). 10.1159/000506767 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.P.S. Sharma, J.R. A, B.V.M.M. Kannan, S (2023) Paraneoplastic Manifestation of Primary Squamous Cell Cancer of the Thyroid Gland. Cureus. 10.7759/cureus.39415 [DOI] [PMC free article] [PubMed]
  • 35.K.C. Bible, E. Kebebew, J. Brierley et al., 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer: American Thyroid Association Anaplastic Thyroid Cancer Guidelines Task Force. Thyroid®. 31, 337–386 (2021). 10.1089/thy.2020.0944 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.V. Subbiah, R.J. Kreitman, Z.A. Wainberg et al., Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Ann. Oncol. 33, 406–415 (2022). 10.1016/j.annonc.2021.12.014 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.J.-H. Liao, C.-W. Yang, Y.-C. Hsieh et al., Hypercalcemia unmasks a PTHrP-secreting liver metastasis in papillary thyroid carcinoma. Arch. Osteoporos. 21, 107 (2026). 10.1007/s11657-026-01735-4 [DOI] [PubMed] [Google Scholar]
  • 38.A. Farooki, V. Leung, H. Tala, R.M. Tuttle, Skeletal-Related Events due to Bone Metastases from Differentiated Thyroid Cancer. J. Clin. Endocrinol. Metab. 97, 2433–2439 (2012). 10.1210/jc.2012-1169 [DOI] [PubMed] [Google Scholar]
  • 39.De S. Leo, M. Trevisan, C. Moneta, C. Colombo, Endocrine-related adverse conditions induced by tyrosine kinase inhibitors. Ann. Endocrinol. 84, 374–381 (2023). 10.1016/j.ando.2023.03.009 [DOI] [PubMed] [Google Scholar]
  • 40.S. Ravioli, A. Lafranchi, A.K. Exadaktylos et al., Characteristics and outcome of severe hypercalcemia on admission to the emergency department: a retrospective cohort study. Swiss Med. Wkly. 153, 40069 (2023). 10.57187/smw.2023.40069 [DOI] [PubMed] [Google Scholar]
  • 41.N. Asonitis, A. Angelousi, C. Zafeiris et al., Diagnosis, Pathophysiology and Management of Hypercalcemia in Malignancy: A Review of the Literature. Horm. Metab. Res. 51, 770–778 (2019). 10.1055/a-1049-0647 [DOI] [PubMed] [Google Scholar]
  • 42.G. Hong, T. Xu, W. Chen et al., Primary hyperparathyroidism due to ectopic parathyroid adenoma with bone lesions mimicking skeletal neoplasm: a case report. AME Case Rep. 9, 163–163 (2025). 10.21037/acr-2025-165 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.M. Beheshti, L. Hehenwarter, Z. Paymani et al., 18F-Fluorocholine PET/CT in the assessment of primary hyperparathyroidism compared with 99mTc-MIBI or 99mTc-tetrofosmin SPECT/CT: a prospective dual-centre study in 100 patients. Eur. J. Nucl. Med. Mol. Imaging. 45, 1762–1771 (2018). 10.1007/s00259-018-3980-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.G. El-Hajj Fuleihan, G.A. Clines, M.I. Hu et al., Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 108, 507–528 (2023). 10.1210/clinem/dgac621 [DOI] [PubMed] [Google Scholar]
  • 45.J. Xie, J. Guo, Z. Kanwal et al., (2020) Calcitonin and Bone Physiology: In Vitro, In Vivo, and Clinical Investigations. Int J Endocrinol 2020:1–20. 10.1155/2020/3236828 [DOI] [PMC free article] [PubMed]
  • 46.N.R. Elahmer, S.K. Wong, N. Mohamed et al., Mechanistic Insights and Therapeutic Strategies in Osteoporosis: A Comprehensive Review. Biomedicines. 12, 1635 (2024). 10.3390/biomedicines12081635 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.M.I. Hu, I.G. Glezerman, S. Leboulleux et al., Denosumab for Treatment of Hypercalcemia of Malignancy. J. Clin. Endocrinol. Metab. 99, 3144–3152 (2014). 10.1210/jc.2014-1001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.J.T.W. Zhang, C. Chan, S.Y. Kwun, K.A. Benson, A Case of Severe 1,25-Dihydroxyvitamin D-Mediated Hypercalcemia due to a Granulomatous Disorder. J. Clin. Endocrinol. Metab. 97, 2579–2583 (2012). 10.1210/jc.2012-1357 [DOI] [PubMed] [Google Scholar]
  • 49.A. Nervo, A. Ragni, F. Retta et al., Bone metastases from differentiated thyroid carcinoma: current knowledge and open issues. J. Endocrinol. Invest. 44, 403–419 (2021). 10.1007/s40618-020-01374-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.M. Schlumberger, M. Tahara, L.J. Wirth et al., Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer. N Engl. J. Med. 372, 621–630 (2015). 10.1056/NEJMoa1406470 [DOI] [PubMed] [Google Scholar]
  • 51.B.R. Haugen, E.K. Alexander, K.C. Bible et al., 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid®. 26, 1–133 (2016). 10.1089/thy.2015.0020 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.L.J. Wirth, E. Sherman, B. Robinson et al., Efficacy of Selpercatinib in RET -Altered Thyroid Cancers. N Engl. J. Med. 383, 825–835 (2020). 10.1056/NEJMoa2005651 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.S. O’Callaghan, H. Yau, Treatment of malignancy-associated hypercalcemia with cinacalcet: a paradigm shift. Endocr. Connect. 10, R13–R24 (2021). 10.1530/EC-20-0487 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.S. Ashfaq, W. Shafiq, A.I. Siddiqi et al., Survival Outcomes in Malignancy-related Hypercalcemia: A Tertiary care Single Center Experience. J. Cancer Allied Spec. 10 (2024). 10.37029/jcas.v10i2.675 [DOI] [PMC free article] [PubMed]
  • 55.A. Maniakas, R. Dadu, N.L. Busaidy et al., Evaluation of Overall Survival in Patients With Anaplastic Thyroid Carcinoma, 2000–2019. JAMA Oncol. 6, 1397 (2020). 10.1001/jamaoncol.2020.3362 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.De M. Ridder, E. Van Nieveen, A. Engelsman et al., Anaplastic thyroid carcinoma: a nationwide cohort study on incidence, treatment and survival in the Netherlands over 3 decades. Eur. J. Endocrinol. 183, 203–209 (2020). 10.1530/EJE-20-0080 [DOI] [PubMed] [Google Scholar]
  • 57.A. Piñar-Gutiérrez, A.R. Romero-Lluch, S. Dueñas-Disotuar et al., Bone metastases from differentiated thyroid cancer: characteristics and prognostic factors in a multicenter series. Eur. Thyroid J. 12, e230086 (2023). 10.1530/ETJ-23-0086 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.A. Jannin, L. Lamartina, C. Moutarde et al., Bone metastases from differentiated thyroid carcinoma: heterogenous tumor response to radioactive Iodine therapy and overall survival. Eur. J. Nucl. Med. Mol. Imaging. 49, 2401–2413 (2022). 10.1007/s00259-022-05697-w [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Material 1 (37.7KB, docx)

Data Availability Statement

No datasets were generated or analysed during the current study.


Articles from Endocrine are provided here courtesy of Springer

RESOURCES